Author(s):
Shrutika Krishnadas Patil, Pallavi Bhilaji Jire, Nilesh Gulab Ahire, Sulbha G. Patil, Sunil P. Pawar
Email(s):
skpatil2323@gmail.com
DOI:
10.52711/0975-4385.2025.00029
Address:
Shrutika Krishnadas Patil, Pallavi Bhilaji Jire, Nilesh Gulab Ahire, Sulbha G. Patil, Sunil P. Pawar
P.S.G.V.P Mandal’s College of Pharmacy, Shahada, Dist - Nandurbar, Maharashtra - India. Postal Code: 425409.
*Corresponding Author
Published In:
Volume - 17,
Issue - 2,
Year - 2025
ABSTRACT:
Liquid crystals (LC) resemble liquids but have ordered structure similar to crystalline solids. There are two sorts of LCs based on their generation method. Thermotropic LCs AND Lyotropic LCs Thermotropic compounds are formed by temperature changes in liquids, while lyotropic compounds are made by dissolving them in specific solvents. Both options provide enough molecular mobility for molecules to change locations and reorient themselves, resulting in the formation of LC phases. Thermotropic liquid crystals are typically single-compound systems, whereas lyotropic liquid crystals are solutions made up of many compounds, including solute and solvent This review article focuses on the significance of pharmaceutical liquid crystals in the development of targeted drug delivery systems. This review aims to provide comprehensive information on pharmaceutical liquid crystal technology, including the most recent and sophisticated developments. pharmaceuticals, liquid crystals have demonstrated immense potential in drug delivery systems, enabling controlled release, improved bioavailability, and targeted delivery of active pharmaceutical ingredients. Techniques such as polarized light microscopy (PLM), differential scanning calorimetry (DSC), X-ray diffraction (XRD), and nuclear magnetic resonance (NMR) are instrumental in characterizing liquid crystal phases and structures. Furthermore, innovations in LC-based transdermal systems and responsive drug carriers have paved the way for next-generation therapeutic strategies. This review explores the classification, applications, advantages, and methods of characterization of liquid crystals, with a focus on their latest developments in pharmaceutical technology. The integration of liquid crystals into pharmaceutical formulations signifies a transformative approach toward precision medicine and enhanced therapeutic outcomes.
Cite this article:
Shrutika Krishnadas Patil, Pallavi Bhilaji Jire, Nilesh Gulab Ahire, Sulbha G. Patil, Sunil P. Pawar. Review on Liquid Crystal. Research Journal of Pharmacognosy and Phytochemistry. 2025; 17(2):179-4. doi: 10.52711/0975-4385.2025.00029
Cite(Electronic):
Shrutika Krishnadas Patil, Pallavi Bhilaji Jire, Nilesh Gulab Ahire, Sulbha G. Patil, Sunil P. Pawar. Review on Liquid Crystal. Research Journal of Pharmacognosy and Phytochemistry. 2025; 17(2):179-4. doi: 10.52711/0975-4385.2025.00029 Available on: https://rjpponline.org/AbstractView.aspx?PID=2025-17-2-16
REFERENCES:
1. Prost J. The Physics of Liquid Crystals. Research Gate, (1993).
2. Kawamoto H. The history of liquid crystal display. Proceedings of the IEEE, 460-99, 2002.
3. Mueller-Goymann CC, Hamann HJ. Sustained release from reverse micellar solutions by phase transformation into lamellar liquid crystals. J Control Release, 23, 165-74, 1993.
4. Mueller-Goymann CC, Frank SG. Interaction of lidocaine and lidocaine hydrochloride with liquid crystal structure of topical preparation. Int J Pharm, 29, 147-59, 1986.
5. Bunjes H, Rades T. Thermotropic liquid crystalline drugs. J Pharm Pharmacol, 57, 807-16, 2005.
6. Makai M, Csanyi E, Dekany I, Nemeth Z, Eros I. Structural properties of non-ionic surfactant/glycerol/paraffin lyotropic crystals. Colloid Polym Sci, 281, 839-44, 2003.
7. Makai M, Csanyi E, Nemeth Zs, Palinkas J, Eros I. Structure and drug release of lamellar liquid crystals containing glycerol. Int J Pharm, 256, 95- 107, 2003.
8. Eccleston GM, Beattie L. Microstructural changes during the storage of system containing cetostearyl alcohol/polyxyethylene alkyl ether surfactant. Drug Dev Ind Pharm, 14, 2499-518, 1988.
9. Farkas E, Zelko R, Nemeth Z, Palinkas J, Marton S, Racz I. The effect of liquid crystalline structure on chlorhexidine diacetate release. Int J Pharm, 193, 239–45, 2000.
10. Shah JC, Sadhle Y, Chilukuri DM. Cubic phase gels as drug delivery systems. Adv Drug Deliv Rev, 47, 229-50, 2001.
11. Shah MH, Paradkar A. Cubic liquid crystalline glyceryl monooleate matrices for oral delivery of enzyme. Int J Pharm, 294, 161-171, 2005.
12. Lara MG, Bentley MVLB, Collett JH. In vitro drug release mechanism and drug loading studies of cubic phase gels. Int J Pharm, 293, 241-250, 2005.
13. Stevenson CL, Bennett DB, Ballesteros DL. Pharmaceutical liquid crystals: the relevance of partially ordered systems. J Pharm Sci, 94, 1861- 79, 2005
14. Patterson J, Bary A, Rades T. Physical stability and solubility of the thermotropic mesophases of fenoprofen calcium as pure drug and in a tablet formulation. Int J Pharm Sci, 247,147-57, 2002.
15. Kulichikhin VG, Malkin AY, Papkov SP. Rheological properties of liquid crystalline polymer systems Review. Polymer Science USSR, 26, 499- 524, 1984.
16. Martin A. Physical pharmacy. 4th edn. USA: Lippincott Williams and Wilkins. Printed in India at Gopsons Papers Ltd, Noida, 36-7, 2001
17. Kawamoto H. The history of liquid crystal display. Proceedings of the IEEE, 460-99, 2002.
18. Jean-Marie Lehn, Andreas Herrmann Nicolas Giuseppone “Imine Based Liquid Crystals for The Controlled Release of Bioactive Materials” Patent App. No20090306196
19. Lehn JM, Giuseppone N, Herrmann A, inventors; Firmenich SA, Centre National de la Recherche Scientifique CNRS, Universite Louis Pasteur Strasbourg I, assignee. Imine based liquid crystals for the controlled release of bioactive materials. United States patent US 8,158,135. 2012 Apr 17.
20. Fu ¨hrer, C., Junginger, H., and Friberg, S., Structural studies of ointments. Part 1: X-ray struc ture studies on the hydrophilic ointment DAB 7, J. Soc. Cosmet. Chem., 29:703–716 (1978).
21. Euschen, A., Diffusion in flu ¨ssigkristallinen Silastomeren—ein Beitrag zur Kontrolle der Arz neistofffreisetzung durch Diffusion, Ph.D. Thesis, Universita ¨t des Saarlandes, Saarbru ¨cken, Germany, 1986.
22. Tiemessen, H.L.G.M., Nonionic Surfactant Systems for Transdermal Drug Delivery, Ph.D. Thesis Leiden University, The Netherlands, 1989.
23. Tzeng CW, Abbott DE, Cantor SB et al. (2013) Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis.’ Ann Surg Oncol 20(Suppl 3): 2197–203.
24. Patel PV, Patel JB, Dangar RD, Patel KS, Chauhan KN. Liquid crystal drug delivery system. International Journal of Pharmaceutical and Applied Sciences. 2010;1(1):118–23.
25. Myers G, inventor; Fuisz Technologies Ltd, assignee. Drug delivery systems utilizing liquid crystal structures. United States patent US 5,891,845. 1999 Apr 6.
26. Veyries ML, Couarraze G, Geiger S, Agnely F, Massias L, Kunzli B, Faurisson F, Rouveix B. Controlled release of vancomycin from poloxamer 407 gels. Int J Pharm. 1999 Dec 10;192(2):183–93. doi: 10.1016/s0378-5173(99)00307-5
27. Pallavi Kawara, Vishal Pande, Liquid Crystals: A Novel Approach Drug Delivery System, JETIR June, 2019, Volume-6,402–410.
28. Shaikh Zeba, Liquid Crystalline System: A Novel approach for Drug Delivery, Journal of Biomedical and Pharmaceutical Research 4 (1) 2015, 22–32.
29. Savita Mandan, Maitreyee Chavan, Cubosomes: Future of Therapeutics, International journal of pharmacy and pharmaceutical research, March 2020 Vol.:17, Issue: 4, 60–69.
30. Yogeshvar Tyagi, liquid crystal: An approach to different states of Matter, Pharma innovation journal, 2018, 7(5): 540–545.
31. Rego, J.A.; Harvey, Jamie A.A.; MacKinnon, Andrew L.; Gatdula, Elysse (January 2010). "Asymmetric synthesis of a highly soluble 'trimeric' analogue of the chiral nematic liquid crystal twist agent Merck S1011". Liquid Crystals37 (1): 37–43. doi:10.1080 /02678290903359291.
32. Boyd BJ, Whittaker D V, Khoob S, DaveyG. Hexosome formed from glycerate surfactants Formulation as a colloidal carrier for irinotecan. Internationa Journal of Pharmaceutics, 318: 154–162(2006).
33. Imran Tadwee, Dr. Sadhana Shahi, Vivek Ramteke, Iftequar Syed, Liquid Crystals Pharmaceutical Application: A Review, IJPRAS, Volume 1, issue2 (2012), 06–11.
34. Zahra Karami and Mehrdad Hamidi, Cubosomes: remarkable drug delivery potential, Drug Discovery Today, Volume 5, Number 5, 790–799, May 2016.